Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

AIMS: The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar MSB11022 (Merck) with Humira(®) (AbbVie), sourced from both the US (US reference product [US‐RP]) and Europe (European reference medicinal product [EU‐RMP]). METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyland, Elizabeth, Mant, Tim, Vlachos, Pantelis, Attkins, Neil, Ullmann, Martin, Roy, Sanjeev, Wagner, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137823/
https://www.ncbi.nlm.nih.gov/pubmed/27285856
http://dx.doi.org/10.1111/bcp.13039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137823/
https://www.ncbi.nlm.nih.gov/pubmed/27285856
http://dx.doi.org/10.1111/bcp.13039

Ejemplares similares